Evolving Role and Clinical Evidence in the Global Practice of Balloon Pulmonary Angioplasty

Nishant Jain; Sidney Perkins; Anand Reddy Maligireddy; Kenneth Rosenfield

doi:10.1016/j.iccl.2023.03.008

Evolving Role and Clinical Evidence in the Global Practice of Balloon Pulmonary Angioplasty

Interv Cardiol Clin. 2023 Jul;12(3):417-427. doi: 10.1016/j.iccl.2023.03.008. Epub 2023 Apr 28.

Authors

Nishant Jain¹, Sidney Perkins², Anand Reddy Maligireddy³, Kenneth Rosenfield⁴

Affiliations

¹ Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA. Electronic address: nishanja@med.umich.edu.
² University of Michigan Medical School, Ann Arbor, MI, USA.
³ Division of Cardiology, Mayo Clinic, Scottsdale, AZ, USA.
⁴ Division of Cardiology, Department of Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.

PMID: 37290844
DOI: 10.1016/j.iccl.2023.03.008

Abstract

Balloon pulmonary angioplasty (BPA) was first described in 2001 and now has evolved into a class I indication for inoperable or residual chronic thromboembolic pulmonary hypertension. This review article aims to describe evidence from studies performed at various pulmonary hypertension (PH) centers across the globe, to better understand the role of BPA in chronic thromboembolic pulmonary disease with and without PH. Additionally, we hope to highlight innovations and the ever-changing safety and efficacy profile of BPA.

Keywords: Balloon pulmonary angioplasty; Chronic thromboembolic pulmonary disease; Chronic thromboembolic pulmonary hypertension; Pulmonary endarterectomy; Pulmonary hypertension.

Published by Elsevier Inc.

Publication types

Review

MeSH terms

Angioplasty, Balloon*
Chronic Disease
Humans
Hypertension, Pulmonary*
Pulmonary Artery / surgery
Pulmonary Embolism* / surgery
Treatment Outcome